Cargando…
Metabolic characterization of the natural progression of chronic hepatitis B
BACKGROUND: Worldwide, over 350 million people are chronically infected with the hepatitis B virus (HBV) and are at increased risk of developing progressive liver diseases. The confinement of HBV replication to the liver, which also acts as the central hub for metabolic and nutritional regulation, e...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902991/ https://www.ncbi.nlm.nih.gov/pubmed/27286979 http://dx.doi.org/10.1186/s13073-016-0318-8 |
_version_ | 1782437058806022144 |
---|---|
author | Schoeman, Johannes C. Hou, Jun Harms, Amy C. Vreeken, Rob J. Berger, Ruud Hankemeier, Thomas Boonstra, Andre |
author_facet | Schoeman, Johannes C. Hou, Jun Harms, Amy C. Vreeken, Rob J. Berger, Ruud Hankemeier, Thomas Boonstra, Andre |
author_sort | Schoeman, Johannes C. |
collection | PubMed |
description | BACKGROUND: Worldwide, over 350 million people are chronically infected with the hepatitis B virus (HBV) and are at increased risk of developing progressive liver diseases. The confinement of HBV replication to the liver, which also acts as the central hub for metabolic and nutritional regulation, emphasizes the interlinked nature of host metabolism and the disease. Still, the metabolic processes operational during the distinct clinical phases of a chronic HBV infection—immune tolerant, immune active, inactive carrier, and HBeAg-negative hepatitis phases—remains unexplored. METHODS: To investigate this, we conducted a targeted metabolomics approach on serum to determine the metabolic progression over the clinical phases of chronic HBV infection, using patient samples grouped based on their HBV DNA, alanine aminotransferase, and HBeAg serum levels. RESULTS: Our data illustrate the strength of metabolomics to provide insight into the metabolic dysregulation experienced during chronic HBV. The immune tolerant phase is characterized by the speculated viral hijacking of the glycerol-3-phosphate–NADH shuttle, explaining the reduced glycerophospholipid and increased plasmalogen species, indicating a strong link to HBV replication. The persisting impairment of the choline glycerophospholipids, even during the inactive carrier phase with minimal HBV activity, alludes to possible metabolic imprinting effects. The progression of chronic HBV is associated with increased concentrations of very long chain triglycerides together with citrulline and ornithine, reflective of a dysregulated urea cycle peaking in the HBV envelope antigen-negative phase. CONCLUSIONS: The work presented here will aid in future studies to (i) validate and understand the implication of these metabolic changes using a thorough systems biology approach, (ii) monitor and predict disease severity, as well as (iii) determine the therapeutic value of the glycerol-3-phosphate–NADH shuttle. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-016-0318-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4902991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49029912016-06-12 Metabolic characterization of the natural progression of chronic hepatitis B Schoeman, Johannes C. Hou, Jun Harms, Amy C. Vreeken, Rob J. Berger, Ruud Hankemeier, Thomas Boonstra, Andre Genome Med Research BACKGROUND: Worldwide, over 350 million people are chronically infected with the hepatitis B virus (HBV) and are at increased risk of developing progressive liver diseases. The confinement of HBV replication to the liver, which also acts as the central hub for metabolic and nutritional regulation, emphasizes the interlinked nature of host metabolism and the disease. Still, the metabolic processes operational during the distinct clinical phases of a chronic HBV infection—immune tolerant, immune active, inactive carrier, and HBeAg-negative hepatitis phases—remains unexplored. METHODS: To investigate this, we conducted a targeted metabolomics approach on serum to determine the metabolic progression over the clinical phases of chronic HBV infection, using patient samples grouped based on their HBV DNA, alanine aminotransferase, and HBeAg serum levels. RESULTS: Our data illustrate the strength of metabolomics to provide insight into the metabolic dysregulation experienced during chronic HBV. The immune tolerant phase is characterized by the speculated viral hijacking of the glycerol-3-phosphate–NADH shuttle, explaining the reduced glycerophospholipid and increased plasmalogen species, indicating a strong link to HBV replication. The persisting impairment of the choline glycerophospholipids, even during the inactive carrier phase with minimal HBV activity, alludes to possible metabolic imprinting effects. The progression of chronic HBV is associated with increased concentrations of very long chain triglycerides together with citrulline and ornithine, reflective of a dysregulated urea cycle peaking in the HBV envelope antigen-negative phase. CONCLUSIONS: The work presented here will aid in future studies to (i) validate and understand the implication of these metabolic changes using a thorough systems biology approach, (ii) monitor and predict disease severity, as well as (iii) determine the therapeutic value of the glycerol-3-phosphate–NADH shuttle. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-016-0318-8) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-10 /pmc/articles/PMC4902991/ /pubmed/27286979 http://dx.doi.org/10.1186/s13073-016-0318-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Schoeman, Johannes C. Hou, Jun Harms, Amy C. Vreeken, Rob J. Berger, Ruud Hankemeier, Thomas Boonstra, Andre Metabolic characterization of the natural progression of chronic hepatitis B |
title | Metabolic characterization of the natural progression of chronic hepatitis B |
title_full | Metabolic characterization of the natural progression of chronic hepatitis B |
title_fullStr | Metabolic characterization of the natural progression of chronic hepatitis B |
title_full_unstemmed | Metabolic characterization of the natural progression of chronic hepatitis B |
title_short | Metabolic characterization of the natural progression of chronic hepatitis B |
title_sort | metabolic characterization of the natural progression of chronic hepatitis b |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902991/ https://www.ncbi.nlm.nih.gov/pubmed/27286979 http://dx.doi.org/10.1186/s13073-016-0318-8 |
work_keys_str_mv | AT schoemanjohannesc metaboliccharacterizationofthenaturalprogressionofchronichepatitisb AT houjun metaboliccharacterizationofthenaturalprogressionofchronichepatitisb AT harmsamyc metaboliccharacterizationofthenaturalprogressionofchronichepatitisb AT vreekenrobj metaboliccharacterizationofthenaturalprogressionofchronichepatitisb AT bergerruud metaboliccharacterizationofthenaturalprogressionofchronichepatitisb AT hankemeierthomas metaboliccharacterizationofthenaturalprogressionofchronichepatitisb AT boonstraandre metaboliccharacterizationofthenaturalprogressionofchronichepatitisb |